[HTML][HTML] Efficacy and safety of fezolinetant, a neurokinin-3 antagonist, in treating vasomotor symptoms in postmenopausal women: A systematic review and meta …
Background: Menopause causes a variety of symptoms such as hot flashes and night
sweats. While menopausal hormonal therapy has been used for managing postmenopausal …
sweats. While menopausal hormonal therapy has been used for managing postmenopausal …
Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis
This systematic review and meta-analysis investigated the efficacy and safety of fezolinetant
for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with …
for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with …
[HTML][HTML] Clinical guidelines for managing menopausal symptoms in women with (a history of) breast cancer
J Servayge, AC Verduyn, A Page… - Facts, Views & Vision …, 2023 - ncbi.nlm.nih.gov
Background One in eight women will be diagnosed with breast cancer. At the time of
diagnosis, 75% of patients are postmenopausal. Many will receive anti-hormone therapy …
diagnosis, 75% of patients are postmenopausal. Many will receive anti-hormone therapy …
Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to Menopause.: A systematic review and Meta-Analysis
AAA Elnaga, MA Alsaied, AM Elettreby… - European Journal of …, 2024 - Elsevier
Abstract Background & Objective Vasomotor symptoms (VMS) are the most common
symptoms during menopause including hot flushes and night sweats. They are highly …
symptoms during menopause including hot flushes and night sweats. They are highly …
Phase II study of fezolinetant for treatment of vasomotor symptoms associated with menopause in Japan
K Takamatsu, T Miki, K Miyazaki, A Hashimoto, W He… - …, 2024 - Taylor & Francis
Abstract Objective The phase II STARLIGHT study was conducted to investigate the
efficacy/safety of fezolinetant in Japanese women and identify the optimal dose for future …
efficacy/safety of fezolinetant in Japanese women and identify the optimal dose for future …
RE: How safe is fezolinetant for the treatment of vasomotor symptoms?
SS Moe, BS Thomas, D Perry - 2024 - cfp.ca
We thank Dr. Douxfils and team for their e-letter (1) in response to the PEER team's article
Top studies of 2023 relevant to primary care.(2) The Top Studies of 2023 article is limited in …
Top studies of 2023 relevant to primary care.(2) The Top Studies of 2023 article is limited in …
[HTML][HTML] Fezolinetant
E Gysling - pharma-kritik, 2024 - infomed.ch
Etwa 1½ Stunden nach oraler Einnahme von Fezolinetant werden maximale Plasmaspiegel
erreicht. Die biologische Verfügbarkeit soll über 90% betragen. Das Medikament wird …
erreicht. Die biologische Verfügbarkeit soll über 90% betragen. Das Medikament wird …